iRadimed Q4 2024 revenue range $19.2-$19.4M, record; full-year revenue $73.1-$73.3M, up 11-12% YoY

IRADIMED CORP

2024-FY EPS reported $1.50 revenue$73,242,121

Q4 2024 revenue ~$19.2M-$19.4M, a record; YoY growth 10-11%, sequential growth 5-6%.
Full-year 2024 revenue ~$73.1M-$73.3M vs $65.6M in 2023, YoY growth 11-12%.
Orders booked in Q4 exceeded shipments, building robust backlog for 2025.
CEO Roger Susi cites increasing demand expected to continue through 2025.
Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.